| 汤晓青,陆彦霓,沈丽达.UGT1A1、SLCO1B1基因多态性与伊立替康化疗不良反应的研究进展[J].肿瘤学杂志,2018,24(9):922-927. |
| UGT1A1、SLCO1B1基因多态性与伊立替康化疗不良反应的研究进展 |
| Research Progress on UGT1A1，SLCO1B1 Gene Polymorphism and Adverse Reaction of Irinotecan |
| 投稿时间：2017-06-18 |
| DOI：10.11735/j.issn.1671-170X.2018.09.B016 |
|
 |
| 中文关键词: 伊立替康 UGT1A1基因多态性 SLCO1B1基因多态性 不良反应 |
| 英文关键词:irinotecan UGT1A1gene polymorphism SLCO1B1gene polymorphism adverse reaction |
| 基金项目: |
|
| 摘要点击次数: 1724 |
| 全文下载次数: 386 |
| 中文摘要: |
| 摘 要：伊立替康(Irinotecan，CPT-11)是抗瘤谱广、临床应用广泛的化疗药物之一，但可能发生的不良反应，尤其是严重的剂量限制性毒性(迟发性腹泻和骨髓抑制)常常影响其临床应用。近年来，由基因多态性指导的临床个体化用药成为热点，有研究指出UGT1A1和SLCO1B1基因多态性参与了CPT-11代谢及转运。全文就UGT1A1和SLCO1B1基因多态性与CPT-11化疗不良反应的研究进展作一综述。 |
| 英文摘要: |
| Abstract：Irinotecan(CPT-11) is one of the widely used chemotherapy drugs. However，the drug may cause severe toxicities，especially the dose-limiting toxicity，such as late-onset diarrhea and bone marrow suppression would affect its clinical application. In recent years，the studies focus on the clinical individualized medication in relation to genetic polymorphisms. Studies have shown that UGT1A1 and SLCO1B1 gene polymorphisms are involved in the metabolism and transportation of irinotecan，this paper reviews the research progress on the relationship between UGT1A1，SLCO1B1 gene polymorphisms and adverse reaction of irinotecan. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |